Executive Summary .....................5
SWOT Analysis......6
India Pharmaceutical Industry SWOT ........................ 6
India Political SWOT........................... 7
India Economic SWOT......................... 8
India Business Environment SWOT ............................ 9
India's Pharmaceutical Business Environment Ratings.......10
Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q110....... 10
Limits of Potential Returns ................ 11
Risks to Realisation of Returns .......... 11
India – Market Summary............12
Regulatory Environment............13
Table: Responsibilities Of India's Department Of Pharmaceuticals....................... 14
Pharmaceutical Advertising............... 15
Pharmacovigilance ............................ 15
Recent Regulatory Developments ............................. 16
IP Regime ................... 16
Table: History Of The Indian Patent System............. 17
Patent Disputes........... 18
Counterfeit Medicines........................ 19
Pricing and Reimbursement............... 20
Industry Trends and Developments.................22
Epidemiology.............. 22
Healthcare Sector .............................. 24
Healthcare Funding........................... 26
Healthcare Insurance ........................ 27
Research and Development................ 27
Clinical Trials............. 28
Recent Developments in the Clinical Trials Industry ....................... 29
Active Pharmaceutical Ingredients ........................... 29
Biotechnology Sector ......................... 31
Traditional Medicines........................ 32
Industry Forecast Scenario ........33
Overall Market Forecast.................... 33
Key Growth Factors – Industry.......... 35
Key Growth Factors – Macroeconomic .................... 36
Table: India – Economic Activity, 2007-2014........... 38
Prescription Drug Market Forecast.......................... 39
Patented Product Market Forecast ........................... 40
Generic Drug Market Forecast.......... 41
OTC Medicine Market Forecast ........ 43
Pharmaceutical Trade Forecast ........ 45
Medical Device Market Forecast....... 47
Other Healthcare Data Forecasts............................. 49
Key Risks to BMI's Forecast Scenario...................... 50
Competitive Landscape.............51
Top Ten Pharmaceutical Companies In India According To 2008 Sales ................. 52
Top Ten Pharmaceuticals In India According To 2008 Sales ........... 52
Retail Pharmacy Sector ..................... 53
Table: Major Players In India's Retail Pharmacy Sector................ 54
Recent Pharmaceutical Retail Developments............ 55
Company Profiles.......................56
Leading Multinational Manufacturers ........................... 56
Pfizer .......................... 56
GlaxoSmithKline (GSK)..................... 58
Novartis ...................... 60
Sanofi-Aventis............. 62
Merck & Co ................ 64
Eli Lilly....................... 66
Leading Indigenous Manufacturers ........ 68
Ranbaxy Laboratories........................ 68
Cipla ........................... 71
Dr Reddy's Laboratories ................... 73
Aurobindo Pharmaceutical................ 75
Venus Remedies .......... 77
Granules India............ 79
Nicholas Piramal India...................... 81
Zydus Cadila............... 83
Country Snapshot: India Demographic Data..........................85
Section 1: Population......................... 85
Table: Demographic Indicators, 2005-2030............. 85
Table: Rural/Urban Breakdown, 2005-2030 ............ 86
Section 2: Education and Healthcare ....................... 86
Table: Education, 2002-2005 ............ 86
Table: Vital Statistics, 2005-2030............................. 86
Section 3: Labour Market And Spending Power ....... 87
Table: Employment Indicators, 1996-2001............... 87
Table: Consumer Expenditure, 2000-2012 (US$) ............................ 87
Table: Average Annual Manufacturing Wages, 2000-2012 ............. 88
BMI Methodology .......................89
How We Generate Our Pharmaceutical Industry Forecasts ................. 89
Pharmaceutical Business Environment Ratings Methodology .............. 90
Ratings Overview........ 90
Table: Pharmaceutical Business Environment Indicators ............... 91
Weighting.................... 92
Table: Weighting Of Components............................. 92
Sources ............................ 92
Forecast Tables ..........................93